- Home
- ICG vs PROK Comparison
ICG vs PROK Comparison
Compare ICG & PROK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ICG
- PROK
- Stock Information
- Founded
- ICG 2017
- PROK 2015
- Country
- ICG China
- PROK United States
- Employees
- ICG N/A
- PROK N/A
- Industry
- ICG Semiconductors
- PROK Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ICG Technology
- PROK Health Care
- Exchange
- ICG Nasdaq
- PROK Nasdaq
- Market Cap
- ICG 105.7M
- PROK 85.5M
- IPO Year
- ICG 2023
- PROK N/A
- Fundamental
- Price
- ICG $2.80
- PROK $4.74
- Analyst Decision
- ICG Strong Buy
- PROK Buy
- Analyst Count
- ICG 2
- PROK 4
- Target Price
- ICG $9.25
- PROK $5.33
- AVG Volume (30 Days)
- ICG 346.9K
- PROK 33.1M
- Earning Date
- ICG 08-14-2025
- PROK 08-08-2025
- Dividend Yield
- ICG N/A
- PROK N/A
- EPS Growth
- ICG N/A
- PROK N/A
- EPS
- ICG 0.07
- PROK N/A
- Revenue
- ICG $53,729,346.00
- PROK $306,000.00
- Revenue This Year
- ICG N/A
- PROK $54.34
- Revenue Next Year
- ICG $141.94
- PROK N/A
- P/E Ratio
- ICG $36.80
- PROK N/A
- Revenue Growth
- ICG 384.54
- PROK N/A
- 52 Week Low
- ICG $1.19
- PROK $0.46
- 52 Week High
- ICG $12.04
- PROK $7.13
- Technical
- Relative Strength Index (RSI)
- ICG 66.82
- PROK 92.14
- Support Level
- ICG $1.75
- PROK $0.54
- Resistance Level
- ICG $2.79
- PROK $7.13
- Average True Range (ATR)
- ICG 0.38
- PROK 0.62
- MACD
- ICG 0.13
- PROK 0.47
- Stochastic Oscillator
- ICG 89.18
- PROK 68.59
About ICG Intchains Group Limited
Intchains Group Ltd provides integrated solutions consisting of high-performance ASIC chips and ancillary software and hardware for blockchain applications. Its ASIC chips are designed for several key blockchain algorithms including Blake2bsha3, sha512MD160, Cryptonight V4, Eaglesong, Blake2s and others. The company has built a proprietary technology platform named Xihe Platform, which allows the development of a wide range of ASIC chips with high efficiency and scalability. It designs its ASIC chips in-house, which enables it to leverage proprietary silicon data to deliver products reflecting the latest technological developments. Geographically, it operates in Mainland China, Hong Kong, and Other countries or regions.
About PROK ProKidney Corp.
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's cells isolated from the patient intended for treatment. Its product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.